alexa The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): van Leeuwen M, Damoiseaux J, Duijvestijn A, Tervaert JW

Abstract Share this page

Abstract While the involvement of T cells in atherosclerosis is nowadays well accepted, little is known about the role of B cells. Obviously, B cells as the source of antibodies, in particular antibodies to oxLDL, have gained a lot of attention in atherosclerosis. In addition, B cells do harbour other functions in adaptive immunity. In this review, we provide an overview of the current knowledge on both the role of B cells and antibodies, i.e., anti-oxLDL antibodies, in atherosclerosis. It appears that B cells and also anti-oxLDL antibodies may comprise pro- and anti-atherogenic effects. Therefore, the establishment of effective therapy, targeting B cells or anti-oxLDL antibodies, warrants further research to unravel these opposite effects. This article was published in Autoimmun Rev and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version